Nanoparticle Testing Service now available — learn more.

RELIANCE BIOSCIENCES delivers frontier molecular diagnostics for early Alzheimer’s disease via protein markers from exosomes in blood.

Exosomes are nanoparticles secreted from disease-specific cells and provide personalized and actionable disease insights. Our proprietary immunoassay technology enables high sensitivity exosomal protein detection using blood.

We are a startup from the National Taiwan University with 15 years of experience working with physicians. We have successfully executed an extremely competitive grant of USD 1.1M. Our medical team includes physicians from the National Taiwan University Hospital, Harvard Medical School and Massachusetts General Hospital.

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset
Exosomes from blood for risk assessment of Alzheimer's Disease | Reliance Biosciences

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset

UNMET NEEDS

1
million
Americans living with Alzheimer’s in 2019
1
million
Americans estimated to have Alzheimer’s by 2050
1
million

People worldwide living with Alzheimer’s in 2019

Diagnostics via exosome

our PIPELINE

Early disease assessment:
  • Parkinson's
  • Colon cancer
Diagnostics via exosome
Biotechnology Partnership | Reliance Bio

PARTNERSHIP

We are seeking partnership with diagnostic labs in laboratory-developed test (LDT) of early Alzheimer’s disease in Japan and USA.

TECHNICAL MILESTONES

Seed grant of USD 1.1 million_Reliance Biosciences_Molecular diagnostics via exosomes

1. Seed grant

Seed grant of USD 1.1 million successfully executed.

Licensing_National Taiwan University_Reliance Biosciences_Molecular diagnostics via exosomes

2. Licensing

Exclusively licensed technology from the National Taiwan University.

Prototypes_immunoassay_Reliance Biosciences_molecular diagnostics via exosomes

3. Prototypes

RExo-system completed: (a) RExo-analyzer: multiplex sample preparation & analysis and (b) RExo-assay: multiplex fluidic assay

Agreement_Alzheimer's_Reliance Biosciences

4. Executed Agreement

Fully executed agreement with an Australian Alzheimer organization with 8,500 contact-patient-year samples available for fast-track study on AD, with PET scan data as control.

5. MTA executed

MTA fully executed with Harvard Med School/MGH with 500 samples for early assessment of lung cancer.

6. NDA executed

Multiple NDAs fully executed with pharmas and organizations towards clinical development.